{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-019014","form_type":"8-K","ticker":"MAIA","cik":"0001878313","company_name":"MAIA Biotechnology, Inc.","filed_at":"2025-10-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.951842+00:00","generated_at":"2026-05-17T02:34:05.770349+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"MAIA reports 30-month (912-day) survival for a Phase 2 NSCLC patient; ESMO posters presented","bullets":["One third-line NSCLC patient on ateganosine (THIO) survived 30 months/912 days as of Sep 17, 2025.","THIO-101 Phase 2 trial evaluates ateganosine + cemiplimab in checkpoint-inhibitor-resistant advanced NSCLC.","New Phase 3 THIO-104 trial compares ateganosine+ICI vs chemotherapy in ICI-resistant NSCLC.","Posters presented at ESMO 2025 in Berlin; full posters available on MAIA website.","CEO states >2-year survival is a clear signal of ateganosine's efficacy in eliminating NSCLC tumors."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-019014","json":"https://secwatch.observer/filing/0001493152-25-019014.json","markdown":"https://secwatch.observer/filing/0001493152-25-019014.md","text":"https://secwatch.observer/filing/0001493152-25-019014.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1878313/000149315225019014/0001493152-25-019014-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1878313/000149315225019014/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T02:34:05.770349+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}